Clinical Prospective Study comparing In-house Respiratory Viral Assays With a Highly Multiplexed Commercial Assay developed by SpeeDx

In-house qPCR

In-house qPCR

Nair S¹, Erskine S¹, Lima N¹, Thailavappil P¹, Seehoo R¹, Tan L¹, Carter I², Kok J², Chen S² and Mokany E¹.

In-house qPCR

¹SpeeDx Pty Ltd, National Innovation Centre, Sydney, Australia, 2015; ²Centre for Infectious Disease and Microbiology Laboratory Services -Pathology West, Westmead Hospital, Sydney, Australia, 2145.

Introduction

Multiplex qPCR is often used for the simultaneous detection of respiratory viruses in clinical specimens. Economic and seasonally-driven pressures for faster, accurate sample testing at reduced costs have resulted in an increased need for highly sensitive and specific assays with high throughput for respiratory illnesses. The PlexPCR™ RV 11 (beta) assay (SpeeDx, Australia) detects 11 virus-specific targets in a 2-well format and utilises a novel qPCR technology that provides a powerful tool for multiplexing(1). Here we evaluated this platform in comparison with an inhouse 10-virus targeted multiplex PCR assay which detects a broad range of respiratory viruses(2). 1 Mokany et al JACS (2010) & Clin Chem (2013); 2 Ratnamohan et al Vir J (2014)

Assay comparison								
Well	In-house	PlexPCR™ RV11						
1	Flu A, Flu B, RSV A&B	Flu A, Flu B, RSV A&B, RhV, Internal Control						
2	HPIV 1-3	HPIV 1-4, hMPV, AdV B&C						
3	RhV, EV, hMPV	Flu A: Influenza A RSV A&B: Respiratory Synctial Virus A&B Flu B: Influenza B HPIV 1-4: Human Parainfluenza 1-4						
4		RhV: Rhinovirus hMPV: Human Metapneumovirus AdV B&C: Adenovirus B&C						


Improved workflow with 2 well assay


In-house qPCR

Clinical Evaluation Amplification Curves FluB FluA **RSV** RhV **HPIV** Note: IC signal not shown AdV **hMPV** as samples were preextracted.

Efficient amplification curves seen in highly multiplexed assay

PlexPCR™ utilising novel PlexZyme™ detection





Superior Multiplexing Capacity, Highly Specific & Sensitive

PlexPCR™ vs Westmead In-house Assay

ΓΙ Λ		In-house qPCR			AdV		In-house qPCR			FluB		In-house qPCR		
-	·luA	+	-	Total	•	+		-	Total		TUD	+	-	Total
×	+	26	7	33	×	+	3	3	6	SpeeDx	+	4	0	4
SpeeDx	-	0	171	171	SpeeDx	-	0	198	198		-	0	200	200
	Total	26	178	204		Total	3	201	204		Total	4	200	204
RhV		In-house qPCR			HPIV		In-house qPCR			RSV		In-house qPCR		
		+	-	Total		IPIV	+	-	Total		13 V	+	-	Total
SpeeDx	+	9	12	21	Č	+	3	1	4	ρχ	+	10	0	10
	-	1	182	183	SpeeD	-	0	200	200	Spee	-	0	194	194
	Total	10	194	204	S	Total	3	201	204	S	Total	10	194	204

FluB & RSV results were 100% concordant

No. of clinical samples: 204 Sample type: upper respiratory tract & nasopharyngeal swab tested over 3 days

Resolved Discrepant samples

Target	Discrepant	Resolution for PlexPCR	Method	Sensitivity (%)	Specificity (%)
FluA	7 positives	5 true positive; 2 nt*	GeneXpert	100.0	100.0
RhV	12 positives 1 negative	10 true positive; 1 false positive 1 confirmed negative; 1 nt*	Sequencing	100.0	98.9
hMPV	5 positives	2 confirmed; 3 to be resolved	Sequencing	100.0	97.5
AdV B&C	3 positives	To be resolved	Sequencing	100.0	98.5
HPIV1-4	1 positive	To be resolved	Sequencing	100.0	99.5

* nt – not tested, sample unavailable

Rapid & Robust Performance with Good Clinical Specificity & Sensitivity

Conclusion

The PlexPCR™ RV 11 (beta) assay demonstrated high sensitivity and specificity even in complex multiplex assays with decreased reaction setup from 4 to 2 wells. We found the PlexPCR assay provided a good approach to qPCR with the advantages of a robust performance in multiplex. There are also advantages seen in higher throughput which would have additional cost savings.

